Friday, November 7, 2025
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home Stocks

Amgen Stock: Strong Earnings Overshadowed by Drug Doubts

Felix Baarz by Felix Baarz
August 6, 2025
in Stocks
0
Amgen Stock
0
SHARES
1
VIEWS
Share on FacebookShare on Twitter

Amgen reported stellar quarterly results, with revenue surging 9% to $9.2 billion—exceeding analyst expectations—and adjusted earnings per share jumping 21% to $6.02. The biotech giant also raised its full-year guidance, projecting revenue between $35-$36 billion and higher EPS estimates. However, shares fell nearly 5% as investor enthusiasm was dampened by concerns over its experimental weight-loss drug, MariTide. Analysts questioned its competitiveness against dominant rivals like Ozempic, casting doubt on Amgen’s ability to capitalize on this high-growth market.

Pipeline Performance Under Scrutiny

While drugs like cholesterol treatment Repatha saw sales soar 31% to $696 million, declining revenue for bone therapy Prolia (-4%) highlighted competitive pressures. Despite heavy R&D investment (up 18%), MariTide remains a key uncertainty, with critical trial data expected later this year. The stock, though up 10% year-to-date, lags behind broader indices, reflecting deeper skepticism about Amgen’s long-term growth strategy amid shifting market dynamics.

Ad

Amgen Stock: Buy or Sell?! New Amgen Analysis from November 7 delivers the answer:

The latest Amgen figures speak for themselves: Urgent action needed for Amgen investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from November 7.

Amgen: Buy or sell? Read more here...

Tags: Amgen
Felix Baarz

Felix Baarz

My name is Felix Baarz, and I look back on over fifteen years of experience as a business journalist. I have always been fascinated by the mechanisms and dynamics of global financial markets as well as the complex economic and political interconnections that shape our world. With this passion, I have made a name for myself as an expert on international financial markets and dedicate myself with great commitment to making even the most complex topics understandable and accessible to my readers. My roots lie in Cologne, where I was born and raised. Early on, my curiosity about economic topics and international developments sparked my interest in journalism. After completing my studies, I began my career as a business editor at a respected German trade publication. Here I laid the foundation for my professional career, but my curiosity soon drew me out into the wider world. A turning point in my life was moving to New York, where I lived for six years and gained insight into leading media houses. In this vibrant metropolis, I was able to report firsthand from the heart of the global financial world. From daily developments on Wall Street to major economic policy decisions that make waves worldwide, I had the opportunity to write about central topics that move people and markets alike. This time shaped my perspective and sharpened my view of global interconnections.

Related Posts

Royal Gold Stock
Stocks

Royal Gold Shares Surge to Record High on Acquisition Momentum

September 29, 2025
Unitedhealth Stock
Stocks

UnitedHealth Shares Present Conflicting Outlook for Investors

September 29, 2025
ASML Stock
Stocks

ASML Forges Strategic AI Alliance to Bolster Semiconductor Dominance

September 29, 2025
Next Post
Onward MedicalV Stock

Onward MedicalV Stock: Neurotech Firm Taps Medtech Veteran for Growth

NiSource Stock

NiSource Stock: Strong Earnings Beat Amid Cautious Market Reaction

General Motors Stock

General Motors Stock: Strategic Shifts Boost Market Confidence

Recommended

Monte Rosa Therapeutics Stock

Monte Rosa Therapeutics Shares Surge on Major Novartis Partnership Expansion

2 months ago
Redefining Success: How Franchises Adapt to Economic Shifts and Market Demands

Stock Analysis Criteo CRTO Receives Mixed Ratings and Price Targets

2 years ago
Cryptocurrency Stock Market Today

Navigating Uncertainties The Death Cross in Crypto Mining Stocks

2 years ago
Tesla Stock

Tesla’s AI Pivot: Strategic Masterstroke or High-Stakes Gamble?

2 months ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple Applovin ASML BioNTech Broadcom Coinbase D-Wave Quantum Eli Lilly Fiserv IBM Intel Kraft Heinz Marvell Technology META Micron Microsoft MP Materials MSCI World ETF NIO Nvidia Ocugen Opendoor Oracle Oxford Lane Capital Palantir PayPal Plug Power QuantumScape Realty Income Robinhood Rocket Lab USA Salesforce Strategy Super Micro Computer Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics Wolfspeed
No Result
View All Result

Highlights

Pharmaceutical Stock Defies Expectations with Surprising Rally

Xoma’s Acquisition Bid Reaches Critical Juncture

Kimberly-Clark Shares Plunge Following Major Acquisition

Baidu’s AI Ambitions Fuel Major Analyst Upgrade

IZEA Worldwide Faces Critical Test in Upcoming Earnings Report

French Government’s Surprising Defense of Temu Creates Political Storm

Trending

JPMorgan Equity Premium Income ETF Stock
Dividends

Uncovering the JEPI ETF’s Dual-Pronged Investment Approach

by Felix Baarz
November 7, 2025
0

The JPMorgan Equity Premium Income ETF employs a sophisticated two-component methodology that merges a carefully selected U.S....

SKYX Platforms Stock

SKYX Platforms Shares Tumble Ahead of Earnings Report

November 7, 2025
BigBear.ai Stock

BigBear.ai Shares Face Critical Test with Upcoming Earnings

November 7, 2025
Crinetics Stock

Pharmaceutical Stock Defies Expectations with Surprising Rally

November 7, 2025
Xoma Stock

Xoma’s Acquisition Bid Reaches Critical Juncture

November 7, 2025

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • Uncovering the JEPI ETF’s Dual-Pronged Investment Approach
  • SKYX Platforms Shares Tumble Ahead of Earnings Report
  • BigBear.ai Shares Face Critical Test with Upcoming Earnings

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com